© 1998 American Heart Association, Inc.
Original Contributions |
High-Affinity Arginine Transport of Bovine Aortic Endothelial Cells Is Impaired by Lysophosphatidylcholine
From the Department of Pharmacology (K.-i.K., T.S., S.M., T.M.), the Department of Neurosurgery (K.-i.K., N.H.), Faculty of Medicine, Kyoto University, Kyoto, Japan, the National Cardiovascular Center Research Institute (T.S., T.M.), Suita, Osaka, Japan, and the Department of Molecular Pharmacology (T.S.), Graduate School of Pharmaceutical Sciences, Osaka University, Suita, Osaka, Japan.
Correspondence to Tomoh Masaki, MD, PhD, Director General, National Cardiovascular Center Research Institute, Suita, Osaka 565-8565, Japan. E-mail masaki{at}ri.ncvc.go.jp
Abstract—The mechanisms of endothelial dysfunction characterized by the impaired nitric oxide (NO) release have not yet been clarified. Because the phenomenon is mimicked in vitro by the application of oxidized LDL and its major lipid constituent, lysophosphatidylcholine (LPC), we analyzed their effects on the arginine-NO system, especially on the arginine transport system. LPC inhibited NO release induced by ADP in cultured bovine aortic endothelial cells. The inhibition was attenuated by the excess amount of extracellular arginine. LPC was found to inhibit the arginine transport in bovine aortic endothelial cells, which is mediated by high- and low-affinity components. LPC predominantly impaired the high-affinity component. In the presence of a high concentration of arginine, LPC showed apparently no inhibition of arginine transport, because the low-affinity transporter compensated for the activity. Taken together, the impairment of the high-affinity transport system might account for the inhibition of NO release by LPC. LPC also inhibited arginine transport in the intima of intact bovine aorta. Furthermore, LPC inhibited the activity of the high-affinity arginine transporter in endothelial cells, in the cationic amino acid transporter-1 expressed in COS-7 cells. The activity of cationic amino acid transporter-1 might be important for the prevention of endothelial dysfunction.
Key Words: lysophosphatidylcholine • arginine transporter • nitric oxide • endothelium • lipoprotein, oxidized low-density
This article has been cited by other articles:
 |
|
 |
|
  J. Loscalzo L-Arginine and Atherothrombosis J. Nutr., October 1, 2004; 134(10): 2798S - 2800S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Parnell, J. P. F. Chin-Dusting, J. Starr, and D. M. Kaye In vivo and in vitro evidence for ACh-stimulated L-arginine uptake Am J Physiol Heart Circ Physiol, July 1, 2004; 287(1): H395 - H400. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Vuong, B. Braam, N. Willekes-Koolschijn, P. Boer, H. A. Koomans, and J. A. Joles Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine Nephrol. Dial. Transplant., August 1, 2003; 18(8): 1485 - 1492. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. D. Vuong, B. Braam, N. Willekes-Koolschijn, P. Boer, H. A. Koomans, and J. A. Joles Hypoalbuminaemia enhances the renal vasoconstrictor effect of lysophosphatidylcholine Nephrol. Dial. Transplant., August 1, 2003; 18(88): 1485 - 1492. [Abstract] [Full Text]
|
|
|
|
 |
|
 K. Y. Krotova, S. I. Zharikov, and E. R. Block Classical isoforms of PKC as regulators of CAT-1 transporter activity in pulmonary artery endothelial cells Am J Physiol Lung Cell Mol Physiol, June 1, 2003; 284(6): L1037 - L1044. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Mann, D. L. Yudilevich, and L. Sobrevia Regulation of Amino Acid and Glucose Transporters in Endothelial and Smooth Muscle Cells Physiol Rev, January 1, 2003; 83(1): 183 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. X. Rong, J. W. Berman, M. B. Taubman, and E. A. Fisher Lysophosphatidylcholine Stimulates Monocyte Chemoattractant Protein-1 Gene Expression in Rat Aortic Smooth Muscle Cells Arterioscler Thromb Vasc Biol, October 1, 2002; 22(10): 1617 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. O. Cannon III Oral L-arginine (and other active ingredients) for ischemic heart disease? J. Am. Coll. Cardiol., January 2, 2002; 39(1): 46 - 48. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Watanabe, R. Pakala, S. Koba, T. Katagiri, and C. R. Benedict Lysophosphatidylcholine and Reactive Oxygen Species Mediate the Synergistic Effect of Mildly Oxidized LDL With Serotonin on Vascular Smooth Muscle Cell Proliferation Circulation, March 13, 2001; 103(10): 1440 - 1445. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Uemura, C. G. Fathman, J. B. Rothbard, and J. P. Cooke Rapid and Efficient Vascular Transport of Arginine Polymers Inhibits Myointimal Hyperplasia Circulation, November 21, 2000; 102(21): 2629 - 2635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Loscalzo What We Know and Don't Know About L-Arginine and NO Circulation, May 9, 2000; 101(18): 2126 - 2129. [Full Text] [PDF]
|
|
|
|
|
|
M. Higaki and K. Shimokado Phosphatidylinositol 3-Kinase Is Required for Growth Factor–Induced Amino Acid Uptake by Vascular Smooth Muscle Cells Arterioscler Thromb Vasc Biol, September 1, 1999; 19(9): 2127 - 2132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Drexler Nitric oxide and coronary endothelial dysfunction in humans Cardiovasc Res, August 15, 1999; 43(3): 572 - 579. [Full Text] [PDF]
|
|
|
|
|
|
A. M Dart and J. P.F Chin-Dusting Lipids and the endothelium Cardiovasc Res, August 1, 1999; 43(2): 308 - 322. [Abstract] [Full Text] [PDF]
|
|